Evidence Based Use of T3+T4 Combinations:  
London, UK & Chicago USA, Sunday, November 3, 2019  
A Joint American Thyroid Association® (ATA®)/British Thyroid Association (BTA)/European Thyroid Association (ETA) Symposium

**Agenda**

<table>
<thead>
<tr>
<th>Session 1: The Scientific Background</th>
<th>Chair: Anita Boelen (US)</th>
</tr>
</thead>
</table>
| 07:10-07:40 (30 mins)              | 13:10-13:40 (30 mins)    | **Keynote:** Local Control of Thyroid Hormone Action, DI02 Polymorphisms and the Effects of L-Thyroxine  
Antonio Bianco (US) |
| 07:40-08:00 (20 mins)              | 13:40-14:00 (20 mins)    | Non Classical Actions of Thyroid Hormone  
Lars Moeller (UK) |
| 08:00-08:20 (20 mins)              | 14:00-14:20 (20 mins)    | Thyroid Hormone Transporters and CNS Levels of Thyroid Hormone  
Heike Heuer (UK) |
| 08:20-08:30 (10 mins)              | 14:20-14:30 (10 mins)    | Discussion |

<table>
<thead>
<tr>
<th>Session 2: Dosing Regimes in Clinical Trials of T3/T4</th>
<th>Chair: Birte Nygaard (UK)</th>
</tr>
</thead>
</table>
| 08:30-08:55 (25 mins)                               | 14:30-14:55 (25 mins)    | T3/T4 Dose Equivalence – Clinical and Trial Data  
Francesco Celi (US) |
| 08:55-09:20 (25 mins)                               | 14:55-15:20 (25 mins)    | Target T3 and TSH levels and Slow Release T3  
Colin Dayan (UK) |
| 09:20-09:30 (10 mins)                               | 15:20-15:30 (10 mins)    | Discussion |
| 09:30-09:45 (15 mins)                               | 15:30-15:45 (15 mins)    | Break |

<table>
<thead>
<tr>
<th>Sessions 3: Trial Endpoints - Measuring Benefit</th>
<th>Chair: Anna Sawka (US)</th>
</tr>
</thead>
</table>
| 09:45-10:10 (25 mins)                            | 15:45-16:10 (25 mins)  | Psychological and Quality of Life Measures  
Torquill Watt (UK) |
| 10:10-10:35 (25 mins)                            | 16:10-16:35 (25 mins)  | Biological Outcomes, Biomarkers and Safety Measures  
Anne Cappola (US) |
| 10:35-10:45 (10 mins)                            | 16:35-16:45 (10 mins)  | Discussion, Wrap Up, and Transition to Practical Sessions |

| Session 4: Practical Management of Patients on T3 and NDT | Chair: Colin Dayan (UK)  
Chair: Jacqueline Jonklaas (US) |
|----------------------------------------------------------|--------------------------|
| N/A (UK only)                                            | 16:45-17:30              | Local expert lead small group workshops on: patient selection; monitoring; stopping therapy; evaluation of response; long term follow-up  
Colin Dayan (UK)  
Eric Fliers (UK) |
| 10:45-11:15 (US only)                                    | Discussion of Patient Experiences on Therapy for Hypothyroidism  
Elizabeth McAninch (US)  
Along with 2 patients |
Endocrinologists are frequently asked to consult on patients taking L-thyroxine (T4) who appear dissatisfied with their therapy. However, the use of combination therapy with liothyronine (T3) remains highly controversial with conflicting results from clinical trials. Recent scientific studies have provided new insight into the complex relationship between serum and tissue thyroid hormone levels justifying a review of the evidence base for the use of T4+T3 combinations and the design of future clinical trials in this area.

This innovative symposium will occur simultaneously in Chicago, US and London, UK, representing a collaborative effort between the ATA, BTA and ETA, to bring together leading experts in this area from North America and Europe. It will be a live meeting in both locations, with the UK audience accessing a webcast to view the US presentations and the US audience accessing a webcast to view the UK presentations with the opportunity for both audiences to ask questions to all speakers. The symposium will conclude with fully interactive workshops on the use of combination therapy in the UK, and a patient discussion forum in the US. Co-chaired by U.S. based Jacqueline Jonklaas, MD and U.K. based Colin M. Dayan, MA, FRCP, PhD, the anticipated goal is to use the symposium content and discussion as material to produce a consensus statement about the design of future combination therapy trials and to assist endocrinologists in advising their patients on the current evidence base behind combination therapy.

**When:** Sunday, November 3, 2019, see agenda on reverse side for times

**Where And How To Register:** For U.S. Participants: Live program included as part of the overall 89th Annual Meeting of the ATA®, October 30 – November 3, 2019 at the Sheraton Grand Chicago, Chicago, IL. Registration for the 89th Annual Meeting of the ATA will open in mid to late May 2019 at www.thyroid.org.

For U.K. Participants: U.K. live program will take place at the Amba Hotel Marble Arch, Bryanston, Street, London, W1H. For further information and registration for London/Europe, email endocrinology&diabetes@cardiff.ac.uk.

**IMPORTANT NOTE:** No virtual stream will be available to attendees not participating in either the US or UK live meetings.

**Participating Faculty:**

Colin M. Dayan, MA, FRCP, PhD, Co-Chair  
Cardiff University  
Cardiff, UK

Anita Boelen, PhD  
University of Amsterdam  
The Netherlands

Eric Fliers, MD, PhD  
University of Amsterdam  
The Netherlands

Lars C. Moeller, MD, PhD  
University of Duisburg  
Essen, Germany

Anna M. Sawka, MD, PhD  
University of Toronto  
Toronto, Ontario, Canada

Jacqueline Jonklaas, MD, Co-Chair  
Georgetown University  
Washington, DC, USA

Anne R. Cappola, MD, ScM  
University of Pennsylvania School of Medicine,  
Philadelphia, PA, USA

Heike Heuer, PhD  
University Hospital Essen  
Essen, Germany

Birte Nygaard, PhD  
Herlev University Hospital  
Copenhagen, Denmark

Torquil Watt, MD, PhD, DMSc  
Herlev University Hospital  
Copenhagen, Denmark

Antonio C. Bianco, MD, PhD  
University of Chicago  
Chicago, IL, USA

Francesco S. Celi, MD  
Virginia Commonwealth University  
Richmond, VA, USA

Elizabeth A. McAninch, MD  
Rush University Medical Center  
Chicago, IL, USA